Pharma BD Deal Intelligence
Celera completed its acquisition of Paracel, exchanging Paracel equity for Celera Genomics shares to add advanced sequence-comparison and text-search…
Six months after the acquisition, Paracel rolled out GeneMatcher 2 under the Celera banner, suggesting near-term execution on the integration thesis.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Celera Genomics completed acquisition of Paracel for ~$245M (closing-price valuation). Brought hardware/software for high-throughput search and manipulation of genetic-information databases. Strengthened Celera's bioinformatics platform during the human-genome publication race.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celera Genomics Group / Paracel Inc. (this deal) | 2000 | $245M | 10 |
| Celera Genomics Group / Axys Pharmaceuticals Inc. | 2001 | $173M | 23 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2000 deals · Other deals